Incidence of Malignant Tumors in Patients with Acromegaly

• Published in: Endocrine Journal Vol. 47; no. SupplMarch; pp. S57 - S60
• Main Authors: HIGUCHI, YOSHINORI, SAEKI, NAOKATSU, IUCH, TOSHIHIKO, UCHINO, YOSHIO, TATSUNO, ICHIRO, UCHIDA, DAIGAKU, TANAKA, TOMOAKI, NOGUCHI, YOSHIHIKO, NAKAMURA, SUSUMU, YASUDA, TOSHIYUKI, YAMAURA, AKIRA, SUNAMI, KENRO, OKA, YOUICHI, UOZUMI, AKIMASA
• Format: Journal Article
• Language: English
• Published: Japan The Japan Endocrine Society 2000
• Subjects: Acromegaly; Acromegaly - complications; Adult; Aged; Cancer incidence; Colon cancer; Female; Humans; Incidence; Male; Malignant tumors; Middle Aged; Neoplasms - complications; Neoplasms - epidemiology; Retrospective Studies; Sex Characteristics; Thyroid cancer
• ISSN: 0918-8959; 1348-4540
• DOI: 10.1507/endocrj.47.SupplMarch_S57

Neoplasms may be one of the systemic complications to which we attribute high mortality in acromegaly. The present study was designed to investigate the incidence of malignant tumors in patients with acromegaly in the Japanese population. In this report, 44 patients (25 men and 19 women) with biochemically proven acromegaly were studied retrospectively and had a total 670 patient years of the duration of acromegaly. We investigated the incidence of malignant tumors. There were 5 patients with malignant tumors (5 in men) in this study (11%). Male patients with acromegaly had nearly a 3.5 times higher ratio of malignancy than expected and this increased cancer incidence was considered significant (P=0.01). There was no significant increase in cancer incidence of either the total patient population or female patients. The malignant tumors were two thyroid cancers and one colon, one gastric and one bladder cancer. It is of note that the colon cancer of one patient was diagnosed 2 years after transsphenoidal surgery even though the levels of serum GH and insulin-like growth factor (IGF-1) were reduced to normal after operation. This preliminary study has suggested that male patients with acromegaly might have a high risk of malignancy and that careful screening for tumors is needed both before and after surgical and medical treatment, even in patients with normalized serum GH and IGF-1 levels.